Ray Dalio's ADMA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 186,471 shares of ADMA Biologics, Inc. (ADMA) worth $3.4 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in ADMA, representing a fresh investment thesis on this company. Largest addition occurred in Q4 2025, adding 126,189 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +126,189 | Add 209.33% | 186,471 | $18.24 |
| Q3 2025 | +60,282 | New Buy | 60,282 | $14.66 |
Ray Dalio's ADMA Biologics Investment FAQs
Ray Dalio first purchased ADMA Biologics, Inc. (ADMA) in Q3 2025, acquiring 60,282 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held ADMA Biologics, Inc. (ADMA) for 2 quarters since Q3 2025.
Ray Dalio's largest addition to ADMA Biologics, Inc. (ADMA) was in Q4 2025, adding 186,471 shares worth $3.4 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 186,471 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $3.4 M.
As of the Q4 2025 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in ADMA Biologics, Inc. (ADMA) was 186,471 shares, as reported at the end of Q4 2025.